Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sangamo Therapeutics (SGMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 683,430
  • Shares Outstanding, K 71,940
  • Annual Sales, $ 19,390 K
  • Annual Income, $ -71,660 K
  • 36-Month Beta 3.26
  • Price/Sales 35.43
  • Price/Cash Flow 0.00
  • Price/Book 5.45

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.30 +14.46%
on 06/22/17
10.50 -9.52%
on 07/14/17
+1.35 (+16.56%)
since 06/21/17
3-Month
4.05 +134.57%
on 04/24/17
10.50 -9.52%
on 07/14/17
+5.45 (+134.57%)
since 04/21/17
52-Week
2.65 +258.49%
on 12/08/16
10.50 -9.52%
on 07/14/17
+3.65 (+62.39%)
since 07/21/16

Most Recent Stories

More News
Sangamo Therapeu Shares Up 42.9% Since SmarTrend's Buy Recommendation (SGMO)

SmarTrend identified an Uptrend for Sangamo Therapeu (NASDAQ:SGMO) on May 11th, 2017 at $6.65. In approximately 2 months, Sangamo Therapeu has returned 42.86% as of today's recent price of $9.50.

SGMO : 9.50 (-0.52%)
Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Sangamo Therapeutics

NEW YORK, NY / ACCESSWIRE / July 17, 2017 / Sangamo's shares catapulted on Friday after the company announced the FDA has granted Fast Track designation to its clinical stage in vivo genome editing product...

SGMO : 9.50 (-0.52%)
ACRX : 3.15 (+1.61%)
Relatively Good Performance Detected in Shares of Cara Therapeutic in the Biotechnology Industry (CARA, MDXG, SGMO, DVAX, HRTX)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

SGMO : 9.50 (-0.52%)
CARA : 15.35 (-0.71%)
MDXG : 14.84 (-1.00%)
DVAX : 9.60 (+0.52%)
HRTX : 16.45 (-6.00%)
S&P Joins Dow in Record Territory

S&P Joins Dow in Record Territory

SGMO : 9.50 (-0.52%)
ULTA : 253.40 (-0.91%)
POT : 17.98 (-0.17%)
AXE : 78.35 (-1.20%)
DAL : 52.26 (-1.08%)
Charging Into Earnings Season

Charging Into Earnings Season

SGMO : 9.50 (-0.52%)
Sangamo Receives Fast Track Designation From The FDA For SB-318 And SB-913 In Vivo Genome Editing Product Candidates For The Treatment Of MPS I And MPS II

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SB-318 and SB-913, the Company's clinical stage in vivo...

SGMO : 9.50 (-0.52%)
Amicus Therapeut has the Best Relative Performance in the Biotechnology Industry (FOLD, ENTA, HRTX, SGMO, RDUS)

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

FOLD : 13.53 (-0.59%)
SGMO : 9.50 (-0.52%)
ENTA : 37.47 (+2.88%)
RDUS : 42.22 (-0.28%)
HRTX : 16.45 (-6.00%)
Will Sangamo Therapeutics (SGMO) Crush Estimates at Its Next Earnings Report?

Sangamo Therapeutics (SGMO) boasts a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming earnings beat.

SGMO : 9.50 (-0.52%)
Sangamo Therapeutics reports USD83.4m from public offering of common stock, including the underwriters option

Genomic therapies company Sangamo Therapeutics Inc (Nasdaq:SGMO) revealed on Monday the completion of its public offering of 10,000,000 shares of its common stock at USD7.25 per share.

SGMO : 9.50 (-0.52%)
Uptrend Call Working As Sangamo Therapeu Stock Rises 40.6% (SGMO)

SmarTrend identified an Uptrend for Sangamo Therapeu (NASDAQ:SGMO) on May 11th, 2017 at $6.65. In approximately 2 months, Sangamo Therapeu has returned 40.60% as of today's recent price of $9.35.

SGMO : 9.50 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Support & Resistance

2nd Resistance Point 9.90
1st Resistance Point 9.70
Last Price 9.50
1st Support Level 9.30
2nd Support Level 9.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.